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Obesity is associated with inflammation and type 2 diabetes. Innate immune system com-
prised of cellular and molecular components plays an important role in the inflammatory
reactions. Immune cells like macrophages and their cell surface pattern-recognition recep-
tors (PRRs) are representative for innate immunity promoting inflammatory reactions.The
receptor for advanced glycation end-products (RAGE) is a member of PRRs and a proin-
flammatory molecular device that mediates danger signals to the body. The expression
of RAGE is observed in adipocytes as well as immune cells, endothelial cells, and pan-
creatic β cells under certain conditions. It has been reported that RAGE is implicated in
adipocyte hypertrophy and insulin resistance. RAGE-mediated regulation of adiposity and
inflammation may attribute to type 2 diabetes and diabetic vascular complications.
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Obesity is associated with an increased risk of developing type
2 diabetes, fatty liver disease, hypertension, and vascular com-
plications (1). Proinflammatory and anti-inflammatory bioactive
molecules produced from adipose tissues, known as adipokines,
contribute to the burden of obesity-related diseases (2). Adipose
tissue consists of heterogeneous populations of adipocytes, stro-
mal preadipocytes, immune cells, and vascular cells, and it can
respond rapidly and dynamically to alterations in nutrient excess
caused by enhanced food consumption through adipocyte hyper-
trophy and hyperplasia (3). This results in a local inflammation in
adipose tissue that propagates an overall systemic but chronic low-
grade inflammation associated with the development of obesity-
related comorbidities such as type 2 diabetes and cardiovascular
diseases (2).
INNATE IMMUNITY AND RAGE-MEDIATED INFLAMMATORY
REACTIONS
The innate immune system can act as a double-edged sword
in protecting the host against foreign enemies and destroy-
ing tissues via inflammation. It may represent an evolution-
ary strategy adopted by multicellular organisms to prevent
the survival of cells that would otherwise cause more dis-
astrous consequences in the individuals and their descen-
dants. Toll-like receptors (TLR) and receptor for advanced
glycation end-products (RAGE) can participate in innate
immunity maintaining a delicate balance between clearance
of pathogens and induction of exaggerated inflammatory
responses.
Receptor for advanced glycation end-products is originally
identified for recognizing advanced glycation end-products (AGE)
(4). RAGE belongs to the immunoglobulin superfamily, and
is now known as a member of pattern-recognition receptors
(PRRs) and as a proinflammatory device. RAGE recognizes a
variety of endogenous and exogenous ligands, including AGE,
advanced oxidation protein products, high-mobility group box
protein 1 (HMGB1), calcium-binding S100 proteins, β2-integrin
Mac-1/CD11b, amyloid β peptide/fibril, lipopolysaccharide (LPS),
phosphatidylserine, C1q, and lysophosphatidic acid (LPA) (5). It
has been hypothesized that RAGE engagement of such ligands
causes diabetic vascular complications, atherosclerosis, cancer,
neurodegeneration, and inflammatory diseases (6). Anti-RAGE
antibody treatment is reported to suppress lung metastasis of
cancer cells and to offer a survival advantage to septic mice
(7, 8). Downstream intracellular signaling molecules of RAGE
include NFκB, ERK (extracellular signal-regulated kinase) 1/2,
p38MAPK (mitogen-activated protein kinases), JNK (c-Jun N-
terminal kinases), PKC (protein kinase C), Rac/Cdc42, and TIRAP
and MyD88, adaptor proteins for TLR 2 and 4 (9). A functional link
between RAGE and TLR is thus considered to be in a coordinated
manner (10).
Among the above ligands, HMGB1 is known to be readily
released from necrotic or damaged cells and to be actively secreted
by activated endothelial cells and immune cells such as mono-
cytes, macrophages, dendritic cells, and natural killer cells (11).
HMGB1 can form a complex with proinflammatory molecules
of CpG DNA, LPS, and interleukin 1β, and this further induces
the activation of RAGE signaling (12). HMGB1 is also found to be
expressed in human adipose tissues with the expression levels asso-
ciated with the fat mass and obesity-related genes (13). TLR2 and
4 also recognize HMGB1 and can be involved in HMGB1-induced
cellular responses (14). S100 proteins are a family of over 20 pro-
teins that show a structural similarity with their two EF-hand
Ca2+-binding domains flanked by α-helices. Higher oligomeriza-
tion states of S100 proteins lead to the activation of RAGE (15).
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AGE-modified S100A8/A9 have been reported to strongly acti-
vate inflammatory responses via RAGE (16). S100A8/A9 was also
shown to interact with TLR4 (17). Our groups have also shown
that phosphatidylserine on the surface of apoptotic cells and LPS
are also RAGE ligands (18, 19). Rapid removal of apoptotic cells by
phagocytes is crucial for tissue development, homeostasis, resolu-
tion of inflammation, and prevention of autoimmune responses.
RAGE was found to function as one of the PS receptors that rec-
ognize and initiate apoptotic cell clearance (18). LPS and the lipid
A component responsible for LPS toxicity and known as endo-
toxin were found to directly interact with RAGE (19). LPS is also
a well-known TLR ligand.
RAGE AND ADIPOSITY
Using RAGE and apoE double deficient mice, Ueno et al. demon-
strated that absence of RAGE is associated with decreased epididy-
mal fat weight and smaller adipocyte size, which are significantly
associated with the decrease in atherosclerotic lesions (20). They
also reported that circulating anti-inflammatory adiponectin lev-
els in apoE−/−RAGE−/− were higher than apoE−/−RAGE+/+
mice, and their levels were significantly and inversely associ-
ated with aortic atherosclerosis. Very recently, Monden et al.
demonstrated that RAGE directly regulated adipogenesis and
hypertrophic process of adipocyte differentiation in vitro (21).
Adenoviral overexpression of RAGE markedly increased genera-
tion of hypertrophic adipocytes and RAGE knockdown by using
siRNA system significantly suppressed generation of hypertrophic
adipocytes. Under high fat diet feeding in mice, RAGE deficiency
is associated with less body weight, less epididymal fat weight, less
adipocyte size, higher serum adiponectin, higher expressions of
Glut4 and adiponectin in epididymal fat, and greater insulin sen-
sitivity. It is now acceptable that direct role of RAGE in adipocyte
hypertrophy and insulin resistance (Figure 1). However, RAGE
ligands are still unknown to be involved in the RAGE-dependent
adiposity. Further studies are required to characterize the inter-
plays among a variety of RAGE ligands and inflammatory reactions
in obesity and type 2 diabetes.
FIGURE 1 | RAGE is implicated in obesity, type 2 diabetes, and vascular
diseases. PRRs, pattern-recognition receptors; RAGE, receptor for
advanced glycation end-products; TLRs, toll-like receptors.
RAGE POLYMORPHISMS, OBESITY, AND INFLAMMATION
Several functional single nucleotide polymorphisms have been
identified in human RAGE gene. The G82S occurs in the
ligand-binding V domain of RAGE and affects ligand affinity,
resulting in the enhancement of proinflammatory reactions and
immune/inflammatory diseases (22, 23). In obese subjects, S/S
carriers showed significantly higher concentrations of AGE and
C reactive protein than G allele carrier and lower concentra-
tion of soluble RAGE, a decoy receptor (24). S allele at RAGE
G82S polymorphism may be more closely associated with proin-
flammatory reactions under obese conditions rather than non-
obese status, thus linking to the development of obesity-associated
complications.
We very recently reported that the induction of RAGE expres-
sion in pancreatic β-cell by insufficient leptin action under obesity
conditions could trigger β-cell failure in type 2 diabetes (25). It is
thus considered that RAGE could be a potential targeting receptor
for the prevention and treatment of the development of obesity,
β-cell failure, vascular complications, and inflammation in type 2
diabetes (Figure 1).
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